Clover Health Investments (CLOV) is poised for "strong" 2025 revenue guidance with the outlook for the medical loss ratio "less clear," UBS Securities said Monday in a report.
In Q4 results set for Thursday, "the focus will be on how the company's newfound growth will translate for MLR" and adjusted earnings before interest, taxes, depreciation and amortization, UBS said.
Growth for 2025 "was noted to have come largely from switchers, which should provide for improved economics" relative to new to Medicare Advantage members," UBS said.
The "relatively positive" Advance Medicare Advantage notice for 2026 may boost revenue in 2026, leaving the company on an "upward trajectory," the report said.
UBS raised its price target on Clover Health to $4.50 from $4 and maintained its neutral rating.
Price: 4.23, Change: -0.18, Percent Change: -3.98
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。